dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Dyspepsia Diagnosis

History

  • A detailed medical, social (eg smoking and alcohol intake) and family history reduces the differential diagnoses
  • Review medications for possible causes of dyspepsia eg Ca antagonists, nitrates, theophyllines, bisphosphonates, steroids and nonsteroidal anti-inflammatory drugs (NSAIDs), Aspirin, Acarbose, Orlistat, potassium supplements

Physical Examination

  • Often normal except for epigastric tenderness
  • Other PE findings may help diagnose or exclude other diseases eg right upper quadrant pain with cholelithiasis, palpable abdominal mass in hepatoma, lymphadenopathy in gastric malignancy

Laboratory Tests

  • Complete blood counts and chemistries (eg LFTs, pancreatic amylase) may be performed to identify alarm features or metabolic diseases causing dyspepsia or to investigate patients who have been unresponsive to treatment

Complications

Evaluation of Alarm Symptoms 

  • Symptoms that suggest complicated disease must be recognized and patients referred immediately for further diagnostic testing
    • GI bleeding
    • Epigastric mass
    • Iron-deficiency anemia
    • Persistent vomiting
    • Progressive dysphagia
    • Suspicious barium meal
    • Unintentional weight loss
    • Persistent nocturnal symptoms
    • Family history of upper GI cancer
    • Lymphadenopathy
    • Jaundice
    • Painful swallowing

Non-ulcer Dyspepsia or Functional Dyspepsia

  • Patients have >1 bothersome dyspepsia symptoms (eg epigastric pain or burning, early satiety, postprandial fullness) and without evidence of structural disease, including a normal upper endoscopy, that can explain the symptoms
  • Includes subcategories that can overlap: 
    • Postprandial distress syndrome (dyspepsia symptoms caused by meals): Includes 1 or both of the following for at least 3 days/week: Bothersome postprandial fullness or early satiety 
    • Epigastric pain syndrome (dyspepsia symptoms that do not occur exclusively postprandially and can be improved by meals): Includes at least 1 of the following for at least 1 day/week: Bothersome epigastric pain and/or burning   
  • Criteria must be fulfilled for postprandial distress syndrome and/or epigastric pain syndrome and fulfilled for the last 3 months with symptoms starting at least 6 months prior to diagnosis (Rome IV criteria)
  • No evidence is documented on routine evaluation (including upper endoscopy) of organic, systemic or metabolic disease that can explain the symptoms
  • Patients with this diagnosis should be treated similarly as those with uninvestigated dyspepsia provided they meet the following criteria:
    • No heartburn
    • No NSAID or low-dose Aspirin use
    • Normal blood tests
    • No evidence of an abnormality
  • H pylori eradication therapy is effective for patients with H pylori-positive functional dyspepsia 
    • Patients without symptoms 6-12 months following H pylori eradication therapy can be classified as H pylori-associated functional dyspepsia 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.